SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences (NBIX), Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results